| Code | CSB-MP5861HU |
| Abbreviation | Recombinant Human CD79A&CD79B Heterodimer protein (Active) |
| MSDS | |
| Size | $190 |
| Order now | |
| Image |
|
| Have Questions? | Leave a Message or Start an on-line Chat |
The CD79A/CD79B heterodimer forms the signaling component of the B-cell receptor complex, making it a critical target for therapeutic antibody development in B-cell malignancies and autoimmune disorders. This mammalian-expressed heterodimer, spanning residues 33–143 of CD79A and 29–159 of CD79B, demonstrates quantified binding to anti-CD79A antibodies with an EC50 of 8.0–9.3 ng/mL and to anti-CD79B antibodies with an EC50 of 14.9–17.5 ng/mL in functional ELISA, providing a validated basis for therapeutic antibody epitope mapping, competitive inhibition screening, and blocking antibody characterization. The mammalian expression system supports native disulfide bonding and glycosylation patterns essential for preserving the conformational epitopes recognized by clinical-stage antibodies targeting this complex. With purity exceeding 90% by SDS-PAGE and endotoxin levels below 1.0 EU/μg, this heterodimer meets the quality thresholds commonly required for surface plasmon resonance affinity measurements, bio-layer interferometry kinetic studies, and high-throughput drug discovery campaigns focused on B-cell receptor signaling modulation.
There are currently no reviews for this product.